December 3, 2020
This article was originally posted on MEDpage Today Despite some concern over a novel ocular toxicity, the FDA granted accelerated approval to belantamab mafodotin (Blenrep) for heavily pretreated multiple myeloma following backing from an advisory panel, the first approved therapy that targets the B-cell maturation antigen (BCMA). Belantamab mafodotin is indicated for patients that have failed a...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand